Microneedles (MNs) allow for improved drug delivery through the skin via formation of micropores. For successful transdermal drug delivery, it is crucial that the micropores remain open as drug delivery stops after micropores close. Delaying micropore closure allows for a longer period of drug delivery from each MN treatment. We showed that darker skin types have longer micropore closure timeframes, which may lead to increased drug dosages delivered. Therefore, this work aims to identify a pathway that delays micropore closure and addresses the extended micropore closure time observed in darker skin. Dopamine plays a role in wound healing but its direct role in micropore closure has never been studied. Dopamine shares overlapping pathways with melanin (responsible for skin color) and provides a possible connection between dark skin and delayed micropore healing. In this work micropore formation after microneedle application was assessed to determine if differences in micropore closure were a result of larger initial micropore depth. Next, the influence of micropores and formulation on total drug exposure was assessed in participants with delayed micropore closure timeframes. Lastly, we evaluated dopamine signaling to identify a pathway for delayed micropore closure timeframes in darker pigmented skin. We visualized micropores after microneedle application and showed delayed micropore closure in darker skin despite no difference in initial micropore depth. Our PK data show that drug delivery may differ in darker skin. Lastly, more dopamine was measured in darker skin and dopamine D1 receptor binding delayed cell migration, delaying wound healing in human skin cells.